MDMA (3,4-methylenedioxymethamphetamine) is an oral drug that is a stimulant, empathogen and entactogen. It is a derivative of amphetamine but has more hallucinogenic effects and a risk of hyponatremia; other toxic effects are the same (eg, agitation, seizures, hypertension, hyperthermia). Diagnosis of acute toxicity is by history and physical examination. Monitor for complications or deterioration with cardiac monitoring, ECG, and serum creatinine and sodium. Toxicity is managed with intravenous benzodiazepines for agitation, hypertension, and seizures; fluid restriction or hypertonic intravenous fluids for hyponatremia; and cooling for hyperthermia. Long-term complications may include psychosis and cognitive impairment.
MDMA is a pill that is usually taken in social settings such as dance clubs, concerts, or rave parties. MDMA is a stimulant. At nontoxic doses, it is an empathogen (causes feelings of emotional openness or connection with others) and entactogen (causes feeling of connection with oneself). Empathogenic and entactogenic effects are not auditory or visual hallucinations, which are signs of drug-induced psychosis.
Pills sold as MDMA may also contain MDEA (3,4-methylenedioxy-N-ethylamphetamine, also called "Eve") or MDA (3,4-methylenedioxyamphetamine), which are side products created during the synthesis of MDMA (1). Pills may also contain cathinones, amphetamines, caffeine, cocaine, lysergic acid diethylamide (LSD), or dextromethorphan (2). This heterogeneity of composition, an issue with most illicit substances, is one reason clinicians treating patients with substance misuse should evaluate for multiple substances even when the patient states their intention was to ingest only one illicit substance.
Street names for MDMA include Ecstasy, X, and Molly.
References
1. Freudenmann RW, Spitzer M. The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev. 2004;10(2):89-116. doi:10.1111/j.1527-3458.2004.tb00007.x
2. Saleemi S, Pennybaker SJ, Wooldridge M, Johnson MW. Who is 'Molly'? MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol. 2017;31(8):1056-1060. doi:10.1177/0269881117715596
Pathophysiology of MDMA Use
MDMA increases the release of serotonin into the synaptic cleft and prevents its reuptake. It also increases the release of noradrenaline and dopamine. Life-threatening hyperthermia and hyponatremia are reported more frequently with MDMA ingestion than with other stimulants. This difference may reflect a combination of unique mechanisms of action and the context in which MDMA is consumed.
MDMA increases secretion of arginine vasopressin. When combined with the excessive intake of hypotonic liquid (eg, water) and increased insensible losses (ie, sweating due to activity or fever), hypoosmolar hyponatremia may develop.
The most common route of use of MDMA is ingestion or insufflation ("snorting").
Pharmacokinetics of MDMA include onset of action in 30 to 60 minutes after ingestion and a typical duration of action of 4 to 6 hours.
Symptoms and Signs of MDMA Toxicity
The effects of use of MDMA (or MDA or MDEA) include a state of excitement and disinhibition and accentuates physical sensation, empathy, and feelings of interpersonal closeness. A useful conceptual model of MDMA effects and toxicity is MDMA = LSD + amphetamine. A single dose of MDMA increases heart rate, blood pressure, body temperature and pupil size, like amphetamine, and produces euphoria, difficulty concentrating, and ego dissolution (a sense of being one with the world) like LSD (1).
Pearls & Pitfalls
|
Patients may have hyperthermia and rhabdomyolysis. The severe hyperthermia may induce a coagulopathy or in multi-organ failure.
Hyponatremia may present with cerebral edema, which may cause altered mental status or seizures.
Toxicity may also include tachydysrhythmias, beginning with sinus tachycardia and proceeding to ventricular tachycardia. There may be agitation and hyperactivity and seizures, with possible status epilepticus.
Symptoms and signs reference
1. Holze F, Vizeli P, Müller F, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45(3):462-471. doi:10.1038/s41386-019-0569-3
Diagnosis of MDMA Toxicity
History and physical examination
ECG
Blood and urine tests for electrolytes and kidney function
Rarely, a blood test for serum MDMA concentration
The diagnosis of MDMA (or MDA or MDEA) toxicity is usually made by history and physical examination, and is suggested when a patient provides a history of ingestion of what they believe to be MDMA or an unknown oral drug at a party or club, reports empathogenic/entactogenic effects, and is hyperthermic, tachycardic, and/or hyponatremic.
The basic laboratory evaluation of a patient with suspected use of a xenobiotic is typically performed, including: complete metabolic profile; serum acetaminophen (paracetamol), salicylate, and ethanol concentrations; serum lactate and blood gas; urinalysis; and urine toxicology screen. If the patient has hyponatremia, serum and urine osmolality, and urine sodium and creatinine concentrations should be obtained.
ECG is performed and cardiac monitoring is initiated to detect cardiac arrhythmias.
A blood test for the serum concentration of MDMA can provide definitive diagnosis of acute use, but this test is rarely performed and usually takes at least a week to provide results. MDMA may cross-react with the amphetamine screen on the urine immunoassay because of MDMA's structural similarity to amphetamine. This cross-reaction is neither sensitive nor specific and will vary with the osmolality of the urine sample and the instruments used.
MDMA pills are often adulterated with caffeine (1). Both substances can cause status epilepticus refractory to benzodiazepines. In the patient in status epilepticus, clinicians should combine diagnosis and treatment to minimize the time spent seizing. A reasonable approach is to:
Administer an appropriate dose of a benzodiazepine; repeat if necessary.
Obtain a serum sodium concentration and observe the patient's pulse pressure (the difference between the systolic and diastolic blood pressures). If available, the sodium should be checked using a point of care test at the bedside.
If hyponatremic (serum sodium < 130 mmol/L), give hypertonic saline or sodium bicarbonate. If the patient is acidotic, sodium bicarbonate may be preferred.
If not hyponatremic and still seizing despite multiple doses of benzodiazepines, suspect caffeine toxicity. The patient may require intubation and sedation with propofol or more benzodiazepines in preparation for hemodialysis (preferred) or continuous renal replacement therapy (CRRT).
Obtain blood samples for confirmatory testing.
Hyponatremia is more consistent with MDMA toxicity and can be treated with hypertonic saline. Mild hyponatremia, corresponding to a serum sodium between 130 and 135 mmol/L is unlikely to be sufficiently low to precipitate seizures. It is helpful to note that sodium bicarbonate contains 8% sodium in contrast to 3% hypertonic saline and is usually readily available in emergency departments and intensive care units. No hyponatremia and a pulse pressure over 60 mm Hg is more consistent with caffeine toxicity and is primarily treated with hemodialysis. Continuous renal replacement therapy (CRRT) can be used if hemodialysis is not available (2). Caffeine is an adenosine antagonist. The differential diagnosis depends on distinctive features of caffeine toxicity, which causes a widened pulse pressure and does not cause hyponatremia. Caffeine toxicity should be considered in a patient with a widened pulse pressure and status epilepticus after suspected MDMA ingestion who has no hyponatremia. The only known effective treatment for caffeine-induced status epilepticus is dialysis. Some institutions, usually those with neonatal intensive care units, may be able to rapidly test for serum caffeine concentrations. Treatment should not be delayed to confirm the diagnosis if the clinical presentation is compelling. Status epilepticus from MDMA with no hyponatremia refractory to benzodiazepines may respond to levitiracetam 40 mg/kg or valproic acid 8 mg/kg. If those fail the patient may need anesthetic levels of sedation with propofol. Sedation with propofol also necessitates mechanical ventilation and continuous EEG monitoring to evaluate for nonconvulsive status epilepticus.
Diagnosis references
1. Byrska B, Stanaszek R. Chemical composition of Ecstasy tablets seized in Poland between 2005 and 2020. Forensic Toxicol. 2025;43(1):22-32. doi:10.1007/s11419-024-00691-3
2. Mitsui D, Kamijo Y, Yoshino T, Hanazawa T, Yoshizawa T, Iwase F. Severe caffeine poisoning treated with intermittent hemodialysis under circulatory support. Am J Emerg Med. 2024;76:270.e5-270.e7. doi:10.1016/j.ajem.2023.12.014
Treatment of MDMA Toxicity
For acute ingestion within 2 hours, oral activated charcoal
IV benzodiazepines as initial therapy; additional medications as needed for severe agitation or cardiovascular effects
For hyponatremia, intravenous fluids (ranging from normal saline to hypertonic saline, depending on volume status and severity of hyponatremia)
For hyperthermia, external cooling methods (eg, ice bath, evaporative cooling)
Preventing absorption
In patients who ingested a large number of MDMA pills within the last 2 hours, activated charcoal may prevent absorption. Use of activated charcoal has not been studied in MDMA use; the rationale for this is extrapolation from other xenobiotics. Many clinicians consider a large number of MDMA pills to be more than 10 pills. Most patients ingest 1 to 2 pills, which are likely fully absorbed within 1 hour.
Whole bowel irrigation and gastric lavage typically have no role in MDMA toxicity, and are used only if recommended by a medical toxicologist for extraordinary cases.
Enhancing excretion
The safest approach to enhancing excretion of MDMA is intravenous hydration with an isotonic crystalloid (eg, normal saline). This will also counteract the drug-induced syndrome of inappropriate antidiuretic hormone (SIADH) and treat rhabdomyolysis.
The pKa of MDMA is approximately 9.6, which is a weak base (1). There is no role for urinary alkalinization or acidification. Urinary alkalinization is only helpful for weak acids. Urinary acidification is generally harmful.
Mitigating toxicity
Benzodiazepines are used to treat the sympathomimetic toxidrome (delirium, hypertension, seizures, and hyperthermia), central nervous system excitation (including agitation and seizures), and also to control tachycardia and hypertension. Management is similar to amphetamine toxicity, which is discussed in detail separately.
Hyponatremia is treated based on severity. Isotonic fluid is given for mild hyponatremia (serum sodium concentration 130 to 135 mmol/L). Hypertonic saline is given for serum sodium concentration below 130 mmol/L. Isotonic fluids are also given to treat rhabdomyolysis.
In patients with status epilepticus without hyponatremia who do not respond to benzodiazepines and who have no other cause of the seizures, dialysis should be considered.
External cooling measures and possibly paralysis are used to treat hyperthermia. The patient must be rapidly cooled. A temperature above 40° C is the strongest predictor of mortality after MDMA ingestion (2).
Treatment references
1. Desrosiers NA, Barnes AJ, Hartman RL, et al. Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. Anal Bioanal Chem. 2013;405(12):4067-4076. doi:10.1007/s00216-013-6848-7
2. van Amsterdam J, Brunt TM, Pierce M, van den Brink W. Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review. Neurotox Res. 2021;39(6):2120-2133. doi:10.1007/s12640-021-00416-z
Chronic Use of MDMA
Complications
Some long-term MDMA users develop paranoid psychosis. Cognitive decline may also occur with repeated, frequent use. Those who use MDMA at least monthly for a year have had difficulties coding information into long-term memory, display impaired verbal learning, and are more easily distracted (1). Deficits that can persist for up to 2 years after cessation (2).
Tolerance and dependence
Chronic use of MDMA may cause dependence, similar to amphetamines.
Chronic use references
1. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl). 2004;173(3-4):434-439. doi:10.1007/s00213-004-1791-0
2. Montoya AG, Sorrentino R, Lukas SE, Price BH. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review. Harv Rev Psychiatry. 2002;10(4):212-220.
Key Points
MDMA is a stimulant and empathogen and enactogen (causes feelings of emotional openness or connection).
MDMA is a derivative of amphetamine, but has more hallucinogenic effects and a risk of hyponatremia. Other toxic effects are similar (eg, agitation, seizures, hypertension, hyperthermia). Potential long-term complications include psychosis and cognitive impairment.
Ventricular dysrhythmias, hyperthermia, cerebral edema, and status epilepticus are the most potentially life-threatening toxicities of MDMA.
Diagnose with history and physical examination; evaluate with serum creatinine and sodium concentrations and ECG. Rarely, a serum MDMA concentration is measured if a definitive diagnosis is required.
Caffeine is a frequent contaminant in MDMA pills. Consider caffeine toxicity in a patient with a widened pulse pressure and status epilepticus refractory to benzodiazepines. Caffeine-induced status epilepticus is treated with dialysis.
For patients who took MDMA pills within the previous 2 hours and who can safely tolerate liquids, treat with activated charcoal. Activated charcoal is not a treatment for other routes of use (eg, inhalation, injection).
Treat with benzodiazepines IM or IV to control central nervous system excitement, hypertension, and tachycardia. Additional medications may be needed for severe agitation or cardiovascular effects.
Treat mild hyponatremia (serum sodium concentration 130 to 135 mmol/L) with isotonic IV fluid or more severe hyponatremia (serum sodium concentration < 130 mmol/L) with hypertonic saline.
For hyperthermia, treat with external cooling methods (eg, ice bath).
Drug Information for the Topic
